RecruitingCervical CancerHPV-Related CarcinomaHPV-Related Malignancy
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
3 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.
Sponsor: Precigen, Inc
You may qualify if…
- ✓ Age 18 years and older.
- ✓ Recurrent or metastatic cervical cancer (histologically or cytologically confirmed)
- ✓ Must have been treated with pembrolizumab, either as monotherapy or in combination, for atleast 6 weeks.
- ✓ Subjects must have histologically or cytologically confirmed HPV positive disease
- ✓ Measurable disease that can be accurately measured by RECIST v1.1 criteria
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ✓ Life expectancy ≥ 12 weeks from the time of enrollment.
- ✓ Must have adequate organ function
You may not qualify if…
- ✕ Prior chemotherapy, targeted therapy within 14 days; monoclonal antibody within 4 weeks; unresolved AEs.
- ✕ Immunodeficiency, active autoimmune disease on immunosuppression, or immunosuppressive therapy within 7 days. HIV eligible with disease control.
- ✕ Active hepatitis B (HBsAg+) or hepatitis C (HCV RT-PCR+) within 30 days of enrollment.
- ✕ History of non-infectious pneumonitis or interstitial lung disease.
- ✕ History of endocrine autoimmune disease (exceptions: treated Graves' disease; hypothyroidism on replacement).
- ✕ Live vaccine within 30 days prior to first dose.
- ✕ Patients with presence of other active malignancy within 1 year prior to study entry
- ✕ Known Central Nervous System (CNS) disease
Where it's recruiting
Source: ClinicalTrials.gov · NCT06157151 · last updated 2026-04-23